Marín-Navarrete R, Szerman N

Language: Spanish
References: 18
Page: 395-396
PDF size: 105.86 Kb.

Text Extraction

No abstract.

REFERENCES

1. Drake RE, Wallach MA. Dual diagnosis: 15 years of progress. Psychiatr Serv. 2000;51(9):1126-1129.

2. Substance Abuse and Mental Health Services Administration (SAMHSA) and Center for Susbtance Abuse Treatment (CSAT).Substance Abuse Treatment for Persons with Co-Ocurring Disorders: A treatment Improvement Protocol Vol. 42. Rockville:U.S. Department of Health and Human Services; 2005.

3. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank R, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66(1):17-31.

4. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730-736.

5. Marin-Navarrete R, Benjet C, Borges G, Eliosa-Hernández A, Nanni-Alvarado R, Ayala-Ledesma M et al. Comorbilidad de los trastornos por consumo de sustancias con otros trastornos psiquiátricos en Centros Residenciales de Ayuda- Mutua para la Atención de las Adicciones. Salud Ment. 2013;36(6):471-479.

6. Lev-Ran S, Imtiaz S, Rehm J, Le Foll B. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiological Survey of Alcohol and Related Conditions (NESARC). Am J Addict; 2013;22(2):93-98. doi: 10.1111/j.1521-0391.2013.00304.x.

7. Osher FC, Drake RE. Revising a historia of unmet needs: approaches to care for persons with co-ocurring addictive and mental disorders. Am J Orthopsychiatry. 1996;66(1):4-11.

8. Szerman N, Martinez-Raga J, Peris L, Roncero C, Basurte I, Vega P, Ruíz P et al. Rethinking dual disorders/pathology. Addict Disord Their Treat. 2013;12(1): 1-10. doi: 10.1097/ADT.0b013e31826e7b6a

9. Volkow ND. Drug abuse and mental illness: progress in understanding comorbidity. Am J Psychiatry. 2001;158(8):1181-1183.

10. Torrens M. Patología dual: situación actual y retos de futuro. Adicciones. 2008;20(4):315-319.

11. Szerman N, Lopez-Castroman J, Arias F, Morant C, Babín F, Mesías B, Mesías B, Basurte I, Vega P, Baca-García E. (2011). Dual diagnosis and suicide risk in a Spanish outpatient simple. Subst Use Misuse. 2012;47(4):383-389. doi: 10.3109/10826084.2011.636135

12. Marín-Navarrete R, Medina-Mora ME. Comorbilidades en los Trastornos por Consumo de Sustancias: Un desafío para los servicios de salud en México. In: Medina-Mora ME: La depresión y otros trastornos psiquiátricos. México: Academia Nacional de Medicina de México A. C.; 2015. pp. 39-58.

13. World Health Organization. Programme on Substance Abuse: Approaches to Treatment of Substance Abuse. EE.UU: Wolrd Health Organization. 1993.

14. Badiani A, Belin D, Epstein D, Calu D, Shaham Y. Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci. 2011;12(11):685-700.

15. Szerman N, Martinez-Raga J. Dual disorders: two different mental disorders?. Adv Dual Diagn. 2015;8(2). doi.org/10.1108/ADD-03-2015-0004

16. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry. 2003;160(4):687-695.

17. Marín-Navarrete R, Medina-Mora ME, Tena-Suck A. Breve panorama del tratamiento de las adicciones en México. In: Tena-Suck A, Marin-Navarrete, R. Temas Selectos en Orientación Psicológica VIII: Orientación Psicológica y Adicciones. Distrito Federal: México: Manual Moderno; 2014. pp. 1-7.

18. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence?. Biol Psychiatry. 1998;44(4):269-273.